X

Trial Profile

Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna
Indications Hodgkin's disease
Focus Therapeutic Use

Most Recent Events

31 May 2023 Planned End Date changed from 1 Feb 2023 to 1 Dec 2024.
14 Dec 2021 Results assessing safety and efficacy of pembrolizumab in combination with ICE (PEM-ICE) chemotherapy in relapsed/refractory classic hodgkin lymphoma, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
30 Apr 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com